Should you wish to receive an email alert when this page is updated with a new press release, please register with our Alert Service.



Date Title
30/07/2010 Cosmo reports increased revenues and operating profit in first-half 2010
12/07/2010 Shire Files Suit against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc
31/05/2010 Shire receives LIALDA® Paragraph IV Notice Letter from Zydus Pharmaceuticals
16/04/2010 Cosmo Pharmaceuticals announces drop in book value of shares of Santarus
30/03/2010 Ordinary and extraordinary assembly at BioXell
19/03/2010 Cosmo reports good 2009 results
01/03/2010 Cosmo Pharmaceuticals announces preliminary end result of its tender offer for BioXell
09/02/2010 Cosmo Pharmaceuticals announces preliminary interim result of its tender offer for BioXell
11/12/2009 Cosmo’s CB-03-01 phase II pilot study in acne demonstrates superiority over Retin A®
08/12/2009 Cosmo Pharmaceuticals publishes Public Tender Offer for BioXell
03/12/2009 Cosmo Pharmaceuticals reports completion of enrolment in Phase III EU study of Budesonide MMX® for Ulcerative Colitis
18/11/2009 Cosmo Pharmaceuticals offers to acquire BioXell
30/07/2009 Cosmo reports a strong first half-year 2009
23/03/2009 Cosmo reports strong revenue growth, €9.4 million net profit for 2008 and a confident outlook for 2009
15/12/2008 COSMO ANNOUNCES STRATEGIC COLLABORATION WITH SANTARUS FOR U.S. RIGHTS TO BUDESONIDE MMX® AND RIFAMYCIN SV MMX®
24/11/2008 Cosmo announces Licensing Agreement with Dr. Falk Pharma for Rifamycin SV MMX®
02/09/2008 Cosmo successfully completes the first phase I clinical trial of its anti-androgen, CB-03-01, for the treatment of skin disorder
04/08/2008 Cosmo Pharmaceuticals awarded US patent for use of its MMX™ technology
29/07/2008 Cosmo Pharmaceuticals reports HY results
21/04/2008 Cosmo Pharmaceuticals reports highly positive results from the LMW Heparin MMX™ phase IIb trial for Ulcerative Colitis
01/04/2008 Cosmo initiates phase I trials of CB-03-01
04/03/2008 Cosmo announces full year results 2007


Back to top